Clinical Scorecard: Outcomes Following Curative Hepatectomy for Hepatocellular Carcinoma in Patients With and Without Metabolic-Associated Fatty Liver Disease: Insights from a Western Cohort Study
At a Glance
Category
Detail
Condition
Hepatocellular Carcinoma (HCC)
Key Mechanisms
Influence of metabolic-associated fatty liver disease (MAFLD) on postoperative outcomes
Target Population
Adults undergoing curative-intent hepatic resection for HCC
Care Setting
Western academic medical center
Key Highlights
MAFLD-positive patients were older, more frequently obese and diabetic, and less likely to have cirrhosis.
Open or hybrid resection was more common in MAFLD-positive patients.
MAFLD was not independently associated with overall survival (OS) or disease-free survival (DFS) after adjustment for confounders.
Cirrhosis, impaired performance status, elevated alpha-fetoprotein, and greater tumor burden were principal predictors of outcomes.
Guideline-Based Recommendations
Diagnosis
Histologically confirm HCC in patients undergoing hepatic resection.
Management
Consider metabolic dysfunction in the context of MAFLD when evaluating HCC patients.
Monitoring & Follow-up
Assess liver disease severity and tumor burden in postoperative follow-up.
Risks
Evaluate risks associated with cirrhosis and elevated alpha-fetoprotein levels.
Patient & Prescribing Data
Adults with resectable HCC
Curative-intent hepatic resection is the primary treatment modality.
Clinical Best Practices
Utilize international consensus criteria for defining MAFLD.
Adjust for liver disease severity and tumor burden in outcome assessments.
